Argentina - español - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

eriochem s.a. - melfalano - comprimidos recubiertos - melfalano 2 mg/comprimido

Argentina - español - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

eriochem s.a. - melfalano - comprimidos recubiertos - melfalano 5 mg/comprimido

Argentina - español - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

eriochem s.a. - melfalano - inyectable liofilizado - melfalano (como clorhidrato) 50 mg / frasco ampolla

Unión Europea - español - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agentes antineoplásicos - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Unión Europea - español - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mieloma múltiple - agentes antineoplásicos - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

pharmaris peru s.a.c. - melfalan; - comprimido recubierto - por comprimido; melfalan 2.000000 mg; - melfalan

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

oqcorp sociedad anonima cerrada - oqcorp s.a.c. - droguerÍa - melfalan; - polvo para concentrado para solucion para perfusion - por vial 1.00 vial - - melfalan

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

pharmaris peru s.a.c. - melfalan; - polvo liofilizado para solucion inyectable - por vial1 vial; melfalan 50.000000 mg; - melfalan

Chile - español - ISPC (Instituto de Salud Pública de Chile)

varifarma chile s.p.a. - melfalan - sin formulas

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zentiva k.s. - melfalan hidrocloruro - polvo y disolvente para soluciÓn inyectable y para perfusiÓn - 50 mg - melfalan hidrocloruro 50 mg - melfalán